| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.17M | 7.17M | 6.18M | 5.86M | 5.80M | 21.30M |
| Gross Profit | 402.79K | -1.42M | -2.15M | -288.23K | -4.36M | -3.27M |
| EBITDA | -5.14M | -4.30M | -6.26M | -5.95M | -1.29M | -5.34M |
| Net Income | -5.21M | -5.21M | -7.36M | -9.16M | -4.15M | -6.40M |
Balance Sheet | ||||||
| Total Assets | 25.09M | 25.09M | 30.35M | 36.24M | 44.60M | 43.11M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.69M | 6.13M | 2.01M | 2.43M | 6.23M |
| Total Debt | 48.45K | 48.45K | 2.25M | 1.04M | 1.09M | 6.49M |
| Total Liabilities | 1.44M | 1.44M | 3.62M | 2.72M | 4.65M | 9.12M |
| Stockholders Equity | 23.85M | 23.85M | 26.87M | 33.59M | 16.05M | 33.99M |
Cash Flow | ||||||
| Free Cash Flow | -3.46M | -3.46M | -4.72M | -7.91M | -6.90M | -7.11M |
| Operating Cash Flow | -3.28M | -3.28M | -4.44M | -7.05M | -3.80M | -2.03M |
| Investing Cash Flow | -47.59K | -47.59K | 6.73M | 6.18M | 3.10M | 1.07M |
| Financing Cash Flow | -94.51K | -94.51K | 1.80M | 449.98K | -3.07M | 796.49K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$133.60M | 19.05 | 10.07% | 2.19% | 38.25% | 361.54% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | AU$120.71M | 21.77 | 13.97% | ― | 28.66% | ― | |
51 Neutral | AU$1.81B | -215.77 | -0.68% | 1.95% | 0.49% | -127.84% | |
40 Underperform | AU$20.81M | -3.47 | -20.54% | ― | 13.92% | 36.28% | |
40 Underperform | AU$36.02M | -0.23 | ― | ― | 1.03% | -52.56% | |
38 Underperform | AU$21.00M | -5.17 | -29.43% | ― | 102.21% | 69.47% |
Australian Dairy Nutritionals Group has announced a change in the director’s interest, specifically involving Peter Nathan, who has been issued 1,500,000 unlisted options under the company’s Incentive Plan. This change, approved by shareholders at the recent AGM, reflects the company’s strategy to align management interests with shareholder value, potentially impacting the company’s governance and operational focus.
Australian Dairy Nutritionals Limited announced the issuance of 1,500,000 unquoted equity securities in the form of options expiring on November 7, 2030, with an exercise price of $0.04. This issuance is part of an employee incentive scheme, which is not intended to be quoted on the ASX, and reflects the company’s efforts to incentivize and retain employees, potentially impacting its operational efficiency and market positioning.
At the 2025 Annual General Meeting of Australian Dairy Nutritionals Limited, a significant development was the second strike against the adoption of the Remuneration Report, with over 25% of votes cast against it. This outcome indicates potential shareholder dissatisfaction with executive compensation. However, the proposal for a Board Spill Meeting was not approved, meaning no immediate changes to the board are required. The meeting also saw the approval of several resolutions, including the re-election of a director and the issuance of options and performance rights, reflecting ongoing strategic initiatives to strengthen the company’s leadership and financial flexibility.
Australian Dairy Nutritionals Limited held its 2025 Annual General Meeting, where the CEO presented to shareholders. The meeting was an opportunity for the company to communicate its current operations and future outlook. This event underscores AHF’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.
Australian Dairy Nutritionals Group reported a consolidated revenue of $1.9 million for the first quarter of fiscal year 2026, with nutritional powder sales contributing $1.3 million. This marks a significant increase in revenue compared to the same period last year, driven by increased distribution of the Future brand in China and contract pack sales. The company also achieved a record production of 67 tonnes, reflecting a strong demand for its products. The Group is focused on expanding its distribution in China and anticipates continued sales and production momentum. Despite a net cash outflow from operations, the financial results are in line with expectations, supporting the company’s strategy to grow as a profitable infant formula export business.